Impact of smoking on clinical outcomes in NMOSD and MOGAD: A meta-analysis.

Mult Scler Relat DisordJul 25, 2026 (epub)
Clinical ResearchNeurology

Bassel Alrabadi, Hasan Matar, Natalie Bandak et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the impact of smoking on clinical outcomes in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Analyzing ten studies, it found that smokers had a significantly higher risk of incomplete recovery following relapses (RR=1.73, 95% CI 1.36-2.20; p<0.0001), with a stronger association in MOGAD (RR=2.41, 95% CI 1.82-3.19; p<0.0001).

Key findings

  • No significant association between smoking and NMOSD-AQP4 incidence (RR=0.76, 95% CI 0.48-1.20; p=0.24).
  • Smokers had a significantly higher risk of incomplete recovery following relapses (RR=1.73, 95% CI 1.36-2.20; p<0.0001).
  • Stronger association of smoking with incomplete recovery in MOGAD (RR=2.41, 95% CI 1.82-3.19; p<0.0001) compared to NMOSD-AQP4 (RR=1.62, 95% CI 1.38-1.90; p<0.0001).
  • Qualitative synthesis suggested poorer MRI lesion resolution among smokers.

Why it matters

Understanding the impact of smoking on recovery in NMOSD and MOGAD is crucial for clinicians, as it highlights a modifiable risk factor that may influence patient outcomes and disability progression.

Source

PubMed · PMID 42520507

Published in Mult Scler Relat Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.